OREANDA-NEWS. Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended March 31, 2016 as well as guidance for fiscal 2016.

Commenting on the announcement, Akira Kurokawa, President and CEO of Santen, said: 

"In fiscal 2015, Santen’s revenue and operating profit both grew by double-digit percentages to reach record high levels. In Japan, revenue maintained positive momentum with growth of 14% boosted by the sales of new products including EYLEA and Alesion. Overseas revenue grew 44% with contributions from products acquired from Merck & Co., Inc. in 2014 as well as Ikervis which was approved and launched in Europe in 2015.

“Our achievements in fiscal 2015 and outlook for fiscal 2016 represent good progress in our Medium-Term Management Plan which focuses on the areas of product development, business expansion, organization and talent. This plan is based on our vision to develop Santen into a specialized pharmaceutical company with a global presence by 2020.”

Summary of results and forecasts

IFRS basis FY15 actual
(million yen)		 change
(YoY %)		 FY16 forecast
(million yen)		 change
(YoY %)
Revenue 195,291   +20.7 % 204,000   +4.5 %
Operating profit   80,180   +126.7 % 38,700   -51.7 %
Net profit for the period   53,373   +122.1 % 26,900   -49.6 %
Earnings per share (basic) ? 128.99   ? 64.95  
Core basis* FY15 actual
(million yen)		 change
(YoY %)		 FY16 forecast
(million yen)		 change
(YoY %)
Revenue 195,291   +20.7 % 204,000   +4.5 %
Core operating profit 43,067   +10.2 % 46,000   +6.8 %
Core net profit for the period 29,163   +12.4 % 31,800   +9.0 %

* Core basis results are non-IFRS measures that remove non-core items including amortization associated with products, other revenue and expenses, and financial revenue and expenses in order to provide greater transparency on underlying business performance.

On August 3, 2015, Santen completed the simplified company split relating to the transfer of its anti-rheumatic pharmaceutical business to AYUMI Pharmaceutical Corporation. The one-time gain related to the transaction resulted in a 45 billion yen positive impact as other income in Santen's FY15 operating profit (IFRS basis).